Is this you? Create Your Porfile
Avatar

Burkhard Haase

Aventis Pharma

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Burkhard Haase is active.

Explore More

Publication

Featured researches published by Burkhard Haase.

Archive | 1996

Cyclic and heterocyclic N-substituted alpha-iminohydroxamic and -carboxylic acids

Werner Thorwart; Wilfried Schwab; Manfred Schudok; Burkhard Haase; Eckart Bartnik; Klaus-Ulrich Weithmann

Journal of Medicinal Chemistry | 1999

Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis.

Hans Matter; Wilfried Schwab; Denis Barbier; Gunter Billen; Burkhard Haase; Bernhard Neises; Manfred Schudok; Werner Thorwart; Herman Schreuder; Volker Brachvogel; Petra Lönze; Klaus Ulrich Dr Weithmann

Bioorganic & Medicinal Chemistry | 2002

Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship.

Hans Matter; Manfred Schudok; Wilfried Schwab; Werner Thorwart; Denis Barbier; Gunter Billen; Burkhard Haase; Bernhard Neises; Klaus-Ulrich Weithmann; Theo Wollmann

Archive | 1998

Substituted diaminocarboxylic acid

Werner Thorwart; Wilfried Schwab; Manfred Schudok; Burkhard Haase; Bernhard Neises; Gunter Billen

Archive | 1995

New cyclic alpha-imino:hydroxamic acid derivatives

Werner Thorwart; Wilfried Schwab; Manfred Schudok; Burkhard Haase; Eckart Bartnik; Klaus-Ulrich Weithmann

Archive | 2002

Formulation with an improved therapeutic range, containing nucleotide synthesis inhibitors

Jürgen Lindner; Burkhard Haase

Archive | 1999

N-arylsulfonyl amino acid omega-amides

Wilfried Schwab; Werner Thorwart; Manfred Schudok; Burkhard Haase

Archive | 1999

N-arylsulfonylamino acid omega-amides

Wilfried Schwab; Werner Thorwart; Manfred Schudok; Burkhard Haase

Archive | 2000

Method for finding nucleotide synthesis inhibitors having fewer side effects

Juergen Lindner; Burkhard Haase

Archive | 2005

Preparation having improved therapeutic breadth comprising nucleotide synthesis inhibitors

Jürgen Lindner; Burkhard Haase

Explore More

Collaboration

Dive into the Burkhard Haase's collaboration.

Top Co-Authors
Avatar

Manfred Schudok

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Werner Thorwart

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Wilfried Schwab

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Klaus-Ulrich Weithmann

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Eckart Bartnik

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Juergen Lindner

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Bernhard Neises

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Gunter Billen

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Jürgen Lindner

Aventis Pharma

View shared research outputs
Top Co-Authors
Avatar

Denis Barbier

Aventis Pharma

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge